These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 22037257)

  • 1. Distinct patterns of promoter CpG island methylation of breast cancer subtypes are associated with stem cell phenotypes.
    Park SY; Kwon HJ; Choi Y; Lee HE; Kim SW; Kim JH; Kim IA; Jung N; Cho NY; Kang GH
    Mod Pathol; 2012 Feb; 25(2):185-96. PubMed ID: 22037257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Promoter CpG island hypermethylation during breast cancer progression.
    Park SY; Kwon HJ; Lee HE; Ryu HS; Kim SW; Kim JH; Kim IA; Jung N; Cho NY; Kang GH
    Virchows Arch; 2011 Jan; 458(1):73-84. PubMed ID: 21120523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Breast cancer stem cells and intrinsic subtypes: controversies rage on.
    Nakshatri H; Srour EF; Badve S
    Curr Stem Cell Res Ther; 2009 Jan; 4(1):50-60. PubMed ID: 19149630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype.
    Ricardo S; Vieira AF; Gerhard R; Leitão D; Pinto R; Cameselle-Teijeiro JF; Milanezi F; Schmitt F; Paredes J
    J Clin Pathol; 2011 Nov; 64(11):937-46. PubMed ID: 21680574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical-pathologic significance of cancer stem cell marker expression in familial breast cancers.
    Bane A; Viloria-Petit A; Pinnaduwage D; Mulligan AM; O'Malley FP; Andrulis IL
    Breast Cancer Res Treat; 2013 Jul; 140(1):195-205. PubMed ID: 23813303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ALDH1 is a better clinical indicator for relapse of invasive ductal breast cancer than the CD44+/CD24- phenotype.
    Zhong Y; Shen S; Zhou Y; Mao F; Guan J; Lin Y; Xu Y; Sun Q
    Med Oncol; 2014 Mar; 31(3):864. PubMed ID: 24519209
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heterogeneity for stem cell-related markers according to tumor subtype and histologic stage in breast cancer.
    Park SY; Lee HE; Li H; Shipitsin M; Gelman R; Polyak K
    Clin Cancer Res; 2010 Feb; 16(3):876-87. PubMed ID: 20103682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unraveling the roles of CD44/CD24 and ALDH1 as cancer stem cell markers in tumorigenesis and metastasis.
    Li W; Ma H; Zhang J; Zhu L; Wang C; Yang Y
    Sci Rep; 2017 Oct; 7(1):13856. PubMed ID: 29062075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinicopathological significance of cancer stem cell markers CD44 and ALDH1 expression in breast cancer.
    Louhichi T; Ziadi S; Saad H; Dhiab MB; Mestiri S; Trimeche M
    Breast Cancer; 2018 Nov; 25(6):698-705. PubMed ID: 29845398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular subtypes of breast cancer are associated with characteristic DNA methylation patterns.
    Holm K; Hegardt C; Staaf J; Vallon-Christersson J; Jönsson G; Olsson H; Borg A; Ringnér M
    Breast Cancer Res; 2010; 12(3):R36. PubMed ID: 20565864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetic regulation of cancer stem cell genes in triple-negative breast cancer.
    Kagara N; Huynh KT; Kuo C; Okano H; Sim MS; Elashoff D; Chong K; Giuliano AE; Hoon DS
    Am J Pathol; 2012 Jul; 181(1):257-67. PubMed ID: 22626806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of ALDH1A1 in contributing to breast tumour aggressiveness: A study conducted in an African population.
    Gyan E; Green A; Ahenkorah-Fondjo L; Jackson A; Toss MS; Akakpo PK; Derkyi-Kwarteng L; Rahman GA; Owiredu W
    Ann Diagn Pathol; 2021 Apr; 51():151696. PubMed ID: 33460998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An increase in cancer stem cell population after primary systemic therapy is a poor prognostic factor in breast cancer.
    Lee HE; Kim JH; Kim YJ; Choi SY; Kim SW; Kang E; Chung IY; Kim IA; Kim EJ; Choi Y; Ryu HS; Park SY
    Br J Cancer; 2011 May; 104(11):1730-8. PubMed ID: 21559013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer stem cell markers ALDH1 and CD44+/CD24- phenotype and their prognosis impact in invasive ductal carcinoma.
    Rabinovich I; Sebastião APM; Lima RS; Urban CA; Junior ES; Anselmi KF; Elifio-Esposito S; De Noronha L; Moreno-Amaral AN
    Eur J Histochem; 2018 Sep; 62(3):. PubMed ID: 30362671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular Subtype-Specific Expression of MicroRNA-29c in Breast Cancer Is Associated with CpG Dinucleotide Methylation of the Promoter.
    Poli E; Zhang J; Nwachukwu C; Zheng Y; Adedokun B; Olopade OI; Han YJ
    PLoS One; 2015; 10(11):e0142224. PubMed ID: 26539832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The CD44+/CD24- phenotype is enriched in basal-like breast tumors.
    Honeth G; Bendahl PO; Ringnér M; Saal LH; Gruvberger-Saal SK; Lövgren K; Grabau D; Fernö M; Borg A; Hegardt C
    Breast Cancer Res; 2008; 10(3):R53. PubMed ID: 18559090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characteristic genes in luminal subtype breast tumors with CD44+CD24-/low gene expression signature.
    Tsunoda Y; Sakamoto M; Sawada T; Sasaki A; Yamamoto G; Tachikawa T
    Oncology; 2011; 81(5-6):336-44. PubMed ID: 22237177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Basal-like breast cancer displays distinct patterns of promoter methylation.
    Lee JS; Fackler MJ; Lee JH; Choi C; Park MH; Yoon JH; Zhang Z; Sukumar S
    Cancer Biol Ther; 2010 Jun; 9(12):1017-24. PubMed ID: 20505321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. P-cadherin is coexpressed with CD44 and CD49f and mediates stem cell properties in basal-like breast cancer.
    Vieira AF; Ricardo S; Ablett MP; Dionísio MR; Mendes N; Albergaria A; Farnie G; Gerhard R; Cameselle-Teijeiro JF; Seruca R; Schmitt F; Clarke RB; Paredes J
    Stem Cells; 2012 May; 30(5):854-64. PubMed ID: 22389315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer stem cell markers are associated with adverse biomarker profiles and molecular subtypes of breast cancer.
    Tsang JY; Huang YH; Luo MH; Ni YB; Chan SK; Lui PC; Yu AM; Tan PH; Tse GM
    Breast Cancer Res Treat; 2012 Nov; 136(2):407-17. PubMed ID: 23053657
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.